Managing comorbid disease in patients with psoriasis

[...]researchers identified "Th17 cells" (a new type of lymphocyte) as important effector cells in autoimmune diseases. 2 Indeed, the first drug that interferes with the functions of Th17 cells was approved in 2009, its first indication being psoriasis. 3 Secondly, psoriasis is now confirmed as a systemic disease, as serum biomarkers for inflammation are raised in patients with psoriasis. 4 Finally, psoriasis frequently occurs alongside other diseases. 5 This review focuses on comorbid diseases and their relation to psoriasis, and we highlight how the presence of comorbidities influences treatment decisions and management for patients with psoriasis.